Search

Your search keyword '"Eugenia Yupei Chock"' showing total 2 results
Start Over Author "Eugenia Yupei Chock" Publication Year Range Last 10 years
2 results on '"Eugenia Yupei Chock"'

1. Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey

Author

Francis Berenbaum, Jasvinder A Singh, Ali Duarte-García, Jinoos Yazdany, Pedro M Machado, Namrata Singh, Deshire Alpizar-Rodriguez, Zachary S Wallace, Eimear Duff, Rebecca Grainger, Tamer A Gheita, Elizabeth R Graef, Jean W Liew, Michael S Putman, Julia F Simard, Emily Sirotich, Carly Harrison, Philip C Robinson, Sebastian E Sattui, Jeffrey A Sparks, Gary Foster, Suleman Bhana, Wendy Costello, Jonathan S Hausmann, Paul Sufka, Richard Conway, Akpabio Akpabio, Michal Nudel, Manuel F Ugarte-Gil, Michael DiIorio, Mitchell Levine, Evelyn Hsieh, Richard A Howard, John Wallace, Inita Bulina, Kevin Kennedy, Tarin T Moni, Aman Dev Singh, Lina El Kibbi, Chieh Lo, David FL Liew, Monique Gore-Massy, Maggie J Larché, More A Kodhek, Nadine Lalonde, Laura-Ann Tomasella, Richard P Beesley, and Eugenia Yupei Chock

Subjects
Medicine
Abstract

Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28 days or longer, among people with systemic autoimmune rheumatic diseases (SARDs).Methods We analysed data from the COVID-19 Global Rheumatology Alliance Vaccine Survey (2 April 2021–15 October 2021) to identify people with SARDs reporting test-confirmed COVID-19. Participants reported COVID-19 severity and symptom duration, sociodemographics and clinical characteristics. We reported the proportion experiencing prolonged symptom duration and investigated associations with baseline characteristics using logistic regression.Results We identified 441 respondents with SARDs and COVID-19 (mean age 48.2 years, 83.7% female, 39.5% rheumatoid arthritis). The median COVID-19 symptom duration was 15 days (IQR 7, 25). Overall, 107 (24.2%) respondents had prolonged symptom duration (≥28 days); 42/429 (9.8%) reported symptoms lasting ≥90 days. Factors associated with higher odds of prolonged symptom duration included: hospitalisation for COVID-19 vs not hospitalised and mild acute symptoms (age-adjusted OR (aOR) 6.49, 95% CI 3.03 to 14.1), comorbidity count (aOR 1.11 per comorbidity, 95% CI 1.02 to 1.21) and osteoarthritis (aOR 2.11, 95% CI 1.01 to 4.27). COVID-19 onset in 2021 vs June 2020 or earlier was associated with lower odds of prolonged symptom duration (aOR 0.42, 95% CI 0.21 to 0.81).Conclusion Most people with SARDs had complete symptom resolution by day 15 after COVID-19 onset. However, about 1 in 4 experienced COVID-19 symptom duration 28 days or longer; 1 in 10 experienced symptoms 90 days or longer. Future studies are needed to investigate the possible relationships between immunomodulating medications, SARD type/flare, vaccine doses and novel viral variants with prolonged COVID-19 symptoms and other postacute sequelae of COVID-19 among people with SARDs.

Published
2022
Full Text
View/download PDF

2. Increased risk of acute and chronic microvascular renal lesions associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: A systematic review and meta-analysis

Author

Vinicius Domingues, Eugenia Yupei Chock, Virginie Dufrost, Jessie Risse, Surya V. Seshan, Medha Barbhaiya, Hervé Sartelet, Doruk Erkan, Denis Wahl, and Stephane Zuily

Subjects
Cross-Sectional Studies, Antibodies, Anticardiolipin, Immunoglobulin G, Lupus Coagulation Inhibitor, Immunology, Antibodies, Antiphospholipid, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, Antiphospholipid Syndrome, Kidney, Lupus Nephritis, Glycoproteins
Abstract

Microvascular renal lesions have been described in patients with antiphospholipid antibodies (aPL), however their association with aPL is inconsistent among studies. Therefore, our objective was to investigate associations between microvascular renal lesions and aPL among systemic lupus erythematosus (SLE) patients.Studies were selected if they included SLE patients with and without aPL positivity with a description of kidney biopsy identifying acute and/or chronic microvascular renal lesions as well as lupus nephritis. Data sources were Pubmed, Embase, Cochrane Library, hand search, congress abstracts, and reference lists of studies, without language restrictions. Risk estimates were independently extracted by 2 investigators. Pooled effect estimates were obtained by using the Mantel-Haenszel method (random effects).Of 1860 identified records obtained between 1991 and 2021, 35 published studies (10 cohorts, 7 case-control, 18 cross-sectional) met inclusion criteria, including 3035 SLE patients according to American College of Rheumatology criteria and 454 cases of microvascular renal lesions. Frequency of microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 31.3% vs. 10.4%, respectively. The overall pooled odds ratios (OR) for microvascular renal lesions in aPL-positive vs. aPL-negative SLE patients was 3.03 (95% confidence interval [CI], 2.25-4.09). The risk of microvascular renal lesions was the highest for lupus anticoagulant (OR = 4.84 [95% CI, 2.93 to 8.02]) and IgG anticardiolipin antibodies (OR = 3.12 [95% CI,1.08-9.02]) while the association with anti-βIn SLE patients, aPL-positivity is associated with a significant 3- to 5-fold increased risk for specific microvascular renal lesions. This risk is mainly driven by lupus anticoagulant and IgG anticardiolipin antibodies. Our results support the inclusion of microvascular renal lesions as new criteria for definite antiphospholipid syndrome.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results